Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) — Capital Reinvestment Ratio
Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) has a Capital Reinvestment Ratio of 4.91x as of September 2025, meaning it reinvests 5% of its operating cash flow (CN¥68.66 Million) in capital expenditures (CN¥337.06 Million). See Sinopep-Allsino Biopharmaceutical Co. Lt net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Capital Reinvestment Ratio (2013–2025)
This chart tracks Sinopep-Allsino Biopharmaceutical Co. Ltd. A's Capital Reinvestment Ratio across 11 annual periods. Check Sinopep-Allsino Biopharmaceutical Co. Lt total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2025)
Year-by-year Capital Reinvestment Ratio for Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2025. For live market cap and broader valuation context, see Sinopep-Allsino Biopharmaceutical Co. Lt stock valuation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 2.01x | CN¥681.24 Million | CN¥1.37 Billion | ▼ -26.3% |
| 2024 | 2.72x | CN¥400.12 Million | CN¥1.09 Billion | ▲ +44.4% |
| 2023 | 1.89x | CN¥350.21 Million | CN¥660.64 Million | ▼ -87.4% |
| 2022 | 14.97x | CN¥29.29 Million | CN¥438.36 Million | ▲ +1059.1% |
| 2021 | 1.29x | CN¥180.75 Million | CN¥233.36 Million | ▲ +64.0% |
| 2020 | 0.79x | CN¥141.38 Million | CN¥111.28 Million | ▼ -86.9% |
| 2019 | 5.99x | CN¥46.14 Million | CN¥276.39 Million | ▲ +191.4% |
| 2018 | 2.06x | CN¥96.06 Million | CN¥197.48 Million | ▼ -68.9% |
| 2017 | 6.60x | CN¥11.11 Million | CN¥73.34 Million | ▲ +4544.9% |
| 2014 | 0.14x | CN¥68.18 Million | CN¥9.69 Million | ▼ -74.8% |
| 2013 | 0.56x | CN¥43.67 Million | CN¥24.63 Million | — |